Biotech Values

[DewDiligence]

France permits automatic FoB substitution for new patients, the first EU country to do so:

http://www.gabionline.net/Policies-Legislation/France-to-allow-biosimilars-substitution

Pharmacists in France will now be allowed to substitute a biosimilar for the prescribed (reference) biological as long as the prescribing physician has not marked the prescription as ‘non-substitutable’.
The new law concerning the Social Security budget (Article 47 of the Law of 23 December 2013), which came into effect on 1 January 2014, has adapted provisions that allow the substitution of originators by generics to extend to biosimilars. Substitution of biosimilars is allowed only when initiating a course of treatment…

… France is the first European country to explicitly permit biosimilar substitution. In the European Union (EU), decisions on pharmacy substitution of medicines (whether generic or biosimilar) are made at the Member State level.